These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 3857611)

  • 1. Purification of a vitamin K epoxide reductase that catalyzes conversion of vitamin K 2,3-epoxide to 3-hydroxy-2-methyl-3-phytyl-2,3-dihydronaphthoquinone.
    Mukharji I; Silverman RB
    Proc Natl Acad Sci U S A; 1985 May; 82(9):2713-7. PubMed ID: 3857611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formation of hydroxyvitamin K by vitamin K epoxide reductase of warfarin-resistant rats.
    Fasco MJ; Preusch PC; Hildebrandt E; Suttie JW
    J Biol Chem; 1983 Apr; 258(7):4372-80. PubMed ID: 6833262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Warfarin inhibition of vitamin K 2,3-epoxide reductase in rat liver microsomes.
    Fasco MJ; Principe LM; Walsh WA; Friedman PA
    Biochemistry; 1983 Nov; 22(24):5655-60. PubMed ID: 6652076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and purification of the vitamin K1 2,3 epoxide reductases system from rat liver.
    Begent LA; Hill AP; Steventon GB; Hutt AJ; Pallister CJ; Cowell DC
    J Pharm Pharmacol; 2001 Apr; 53(4):481-6. PubMed ID: 11341364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of vitamin K epoxide to hydroxyvitamin K by liver microsomes from warfarin-resistant rats.
    Nutr Rev; 1983 Aug; 41(8):253-4. PubMed ID: 6355923
    [No Abstract]   [Full Text] [Related]  

  • 6. Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH2.
    Chu PH; Huang TY; Williams J; Stafford DW
    Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19308-13. PubMed ID: 17164330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-purification of microsomal epoxide hydrolase with the warfarin-sensitive vitamin K1 oxide reductase of the vitamin K cycle.
    Guenthner TM; Cai D; Wallin R
    Biochem Pharmacol; 1998 Jan; 55(2):169-75. PubMed ID: 9448739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formation of 3-hydroxy-2,3-dihydrovitamin K1 in vivo: relationship to vitamin K epoxide reductase and warfarin resistance.
    Preusch PC; Suttie JW
    J Nutr; 1984 May; 114(5):902-10. PubMed ID: 6726460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species comparison of vitamin K1 2,3-epoxide reductase activity in vitro: kinetics and warfarin inhibition.
    Wilson CR; Sauer JM; Carlson GP; Wallin R; Ward MP; Hooser SB
    Toxicology; 2003 Aug; 189(3):191-8. PubMed ID: 12832152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of N-methyl-thiotetrazole on vitamin K epoxide reductase.
    Creedon KA; Suttie JW
    Thromb Res; 1986 Oct; 44(2):147-53. PubMed ID: 3787564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue distribution and warfarin sensitivity of vitamin K epoxide reductase.
    Hazelett SE; Preusch PC
    Biochem Pharmacol; 1988 Mar; 37(5):929-34. PubMed ID: 3345202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal and warfarin-resistant rat hepatocyte metabolism of vitamin K 2,3-epoxide: evidence for multiple pathways of hydroxyvitamin K formation.
    Trivedi LS; Rhee M; Galivan JH; Fasco MJ
    Arch Biochem Biophys; 1988 Jul; 264(1):67-73. PubMed ID: 3395132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solubilization and characterization of vitamin K epoxide reductase from normal and warfarin-resistant rat liver microsomes.
    Hildebrandt EF; Preusch PC; Patterson JL; Suttie JW
    Arch Biochem Biophys; 1984 Feb; 228(2):480-92. PubMed ID: 6696443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a warfarin-sensitive protein component in a 200S rat liver microsomal fraction catalyzing vitamin K and vitamin K 2,3-epoxide reduction.
    Lee JJ; Principe LM; Fasco MJ
    Biochemistry; 1985 Dec; 24(25):7063-70. PubMed ID: 4084561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-(Fluoromethyl)-3-phytyl-1,4-naphthoquinone and its 2,3-epoxide. Inhibition of vitamin K epoxide reductase.
    Silverman RB; Oliver JS
    J Med Chem; 1989 Sep; 32(9):2138-41. PubMed ID: 2769684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substituted vitamin K epoxide analogues. New competitive inhibitors and substrates of vitamin K1 epoxide reductase.
    Ryall RP; Nandi DL; Silverman RB
    J Med Chem; 1990 Jun; 33(6):1790-7. PubMed ID: 2342073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin K epoxide reductase activity and its inhibition by warfarin in young and old rats.
    Hallak HO; Wedlund PJ
    Drug Metab Dispos; 1991; 19(1):278-9. PubMed ID: 1673414
    [No Abstract]   [Full Text] [Related]  

  • 18. Lapachol inhibition of vitamin K epoxide reductase and vitamin K quinone reductase.
    Preusch PC; Suttie JW
    Arch Biochem Biophys; 1984 Nov; 234(2):405-12. PubMed ID: 6497379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that warfarin anticoagulant action involves two distinct reductase activities.
    Fasco MJ; Hildebrandt EF; Suttie JW
    J Biol Chem; 1982 Oct; 257(19):11210-2. PubMed ID: 6811577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B16 tumor cells contain a warfarin sensitive vitamin K1 2,3 epoxide reductase.
    Uitendaal MP; Thijssen HH; Drittij-Reijnders MJ; Hoeijmakers MJ
    Biochem Biophys Res Commun; 1986 Jun; 137(3):1015-20. PubMed ID: 3729947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.